Ivabradina Teva Italia

Ivabradine, the active ingredient in Ivabradina Teva Italia, is an If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina and for heart failure with reduced ejection fraction, helping to lower heart rate without affecting contractility in adult patients.

GNH USA supplies Ivabradina Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution.

Ivabradine is an If channel inhibitor used in cardiovascular conditions where heart rate reduction is beneficial. - Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may reduce hospitalisation by decreasing heart rate. - Patients intolerant to beta‑blockers: offers an alternative mechanism to achieve heart‑rate control.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia: excessively low heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness.

Serious or Rare Side Effects: - Severe bradyarrhythmia: symptomatic sinus pause. - Atrial fibrillation: new onset arrhythmia. - Marked hypotension: significant drop in blood pressure.

When prescribing Ivabradine, several safety considerations should be observed. - Dose adjustment: required in patients with hepatic impairment. - Monitoring: regular ECG and heart‑rate assessment recommended. - Contraindication: not for patients with acute decompensated heart failure or severe hypotension. - Caution: avoid use with strong CYP3A4 inhibitors. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Ivabradine can interact with other medicines, necessitating careful review of a patient’s regimen.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels. - Concomitant use with other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Verapamil or diltiazem: potentiate ivabradine effect on heart rate.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Drugs affecting QT interval (e.g., certain antiarrhythmics): monitor ECG for prolongation.